This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bogdanovich, T.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogdanovich, T.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2007, p. 4191-4195, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00550-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents{triangledown}

Tatiana Bogdanovich, Catherine Clark, Klaudia Kosowska-Shick, Bonifacio Dewasse, Pamela McGhee, and Peter C. Appelbaum*

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033

Received 25 April 2007/ Returned for modification 2 July 2007/ Accepted 10 July 2007

Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 µg/ml, with MIC50 and MIC90 values of 0.25 µg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 µg/ml). The daptomycin MICs were 0.25 to 2.0 µg/ml for methicillin-susceptible and 0.25 to 4.0 µg/ml against methicillin-resistant strains (including vancomycin-intermediate strains). Single-passage selection testing showed low resistance frequencies with CG400549, but multistep analysis showed that CG400549 yielded resistant mutants after 14 to 17 days in all strains tested.

* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu

{triangledown} Published ahead of print on 17 September 2007.

Antimicrobial Agents and Chemotherapy, November 2007, p. 4191-4195, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00550-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Clark, C., Kosowska-Shick, K., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Resistance Selection Studies Comparing the Activity of Razupenem (PTZ601) to Vancomycin and Linezolid against Eight Methicillin-Resistant and Two Methicillin-Susceptible Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 53: 3118-3121 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»